Equitable access to direct-acting antivirals: Canada's path to a hepatitis C-free tomorrow.

作者信息

Canani Faranak, Feld Jordan J, Biondi Mia J

机构信息

School of Nursing, York University, Toronto, Canada.

Toronto Centre for Liver Disease/Viral Hepatitis Care Network (VIRCAN), University Health Network, Toronto, Canada.

出版信息

Can Liver J. 2024 Feb 26;7(1):3-4. doi: 10.3138/canlivj-2023-0038. eCollection 2024 Feb.

DOI:10.3138/canlivj-2023-0038

PMID:38505787

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10946179/

Abstract

摘要

相似文献

[1]

Equitable access to direct-acting antivirals: Canada's path to a hepatitis C-free tomorrow.

Can Liver J. 2024-2-26

[2]

Recommendations for Canada's National Action Plan to End Gender-Based Violence: perspectives from leaders, service providers and survivors in Canada's largest city during the COVID-19 pandemic.

Health Promot Chronic Dis Prev Can. 2023-4-12

[3]

Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.

Lancet Public Health. 2023-4

[4]

Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C.

Liver Int. 2020-10

[5]

Canada and access to medicines in developing countries: intellectual property rights first.

Global Health. 2013-9-3

[6]

Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.

Drug Alcohol Rev. 2019-2-13

[7]

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources.

Rev Gastroenterol Mex (Engl Ed). 2018

[8]

Canada's economic situation--what will tomorrow bring?

Dimens Health Serv. 1982-9

[9]

Canada's contribution to global research in cardiovascular diseases.

Can J Cardiol. 2012-12-6

[10]

Regulators deny access to experimental hepatitis C drug.

Can HIV AIDS Policy Law Rev. 2002-12

本文引用的文献

[1]

Timing of elimination of hepatitis C virus in Canada's provinces.

Can Liver J. 2022-11-7

[2]

Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.

Can Liver J. 2023-7-26

[3]

Province-to-province variability in hepatitis C testing, care, and treatment across Canada.

Can Liver J. 2023-7-26

[4]

A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada.

J Viral Hepat. 2023-8

[5]

Uptake and factors associated with direct-acting antiviral therapy for hepatitis C and treatment outcomes among Canadian immigrants: A retrospective cohort analysis.

Can Liver J. 2022-8-16

[6]

Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents.

Liver Int. 2021-8

[7]

Accelerating our response: Government of Canada five-year action plan on sexually transmitted and blood-borne infections.

Can Commun Dis Rep. 2019-12-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Equitable access to direct-acting antivirals: Canada's path to a hepatitis C-free tomorrow.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献